Coya Therapeutics, Inc. SEC Filings

Welcome to our dedicated page for Coya Therapeutics SEC filings (Ticker: COYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The Coya Therapeutics, Inc. (NASDAQ: COYA) SEC filings page provides access to the company’s U.S. Securities and Exchange Commission disclosures, which document its status as a Nasdaq-listed clinical-stage biotechnology company and outline key corporate, financing, and clinical development events. Coya’s common stock, par value $0.0001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Stock Market LLC under the symbol COYA, as noted in multiple Form 8-K filings.

In its recent current reports on Form 8-K, Coya has disclosed material events such as milestone payments received under a Development and License Agreement with Dr. Reddy’s Laboratories Ltd. tied to FDA acceptance of an Investigational New Drug (IND) application for COYA 302 in amyotrophic lateral sclerosis (ALS) and dosing of the first patient in the Phase 2 ALSTARS Trial. Other 8-K filings describe the submission and resubmission of the IND for COYA 302, FDA review timelines, and acceptance of a Clinical Trial Application (CTA) by Health Canada.

Filings also cover capital markets activity, including an Underwriting Agreement for an underwritten public offering of common stock and related details such as the number of shares offered, offering price, estimated gross proceeds, and issuance of warrants to a financial advisor. Additional 8-Ks report quarterly financial results via furnished press releases, as well as outcomes of the company’s annual meeting of stockholders, including director elections and auditor ratification.

On Stock Titan, Coya’s SEC filings are updated as new documents are posted to EDGAR. Users can review 8-Ks related to clinical milestones, financing transactions, and governance matters, alongside other periodic and registration statements, while AI-powered tools help summarize key points and highlight items such as trial progress, milestone payments, and changes affecting COYA shareholders.